Recurrent Melanoma Active Not Recruiting Phase 2 Trials for Sargramostim (DB00020)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01134614Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryTreatment